Clinical-stage biotech
Walk into every partnering and financing conversation with a case that holds up
When a Phase II readout, a financing round or a partnering process sets your valuation, Pixen gives you one connected, defensible biotech asset valuation, and keeps it live as the data moves.
What's at stake
"Your valuation is set in a handful of meetings. Every assumption you can't source becomes a discount."
Defend your valuation.
An rNPV built from sourced, approved assumptions. Answer diligence questions with the source, not a follow-up e-mail.
Own your model.
Keep the case in-house and update it when the science moves, without a new consulting engagement each time.
One story for every audience.
Your board, investors and partners see the same approved profile, forecast and value.
- Financing scenarios linking the development plan to runway, milestones and value
- A secure partner view of an approved case
HX-201, a Phase II asset, modelled across 7 countries plus Rest of World, 2032–2041.
Illustrative data. We never show customer data.
FAQ
For clinical-stage biotech
How quickly can we build our first asset case?
Templates and population imports mean you start from structure, not a blank sheet. We'll walk through a realistic timeline for your asset in the demo.
Can we start before we have a full forecast?
Yes. Modules are switched on per asset. Many teams start with the target product profile and competitive assessment, and switch on valuation when they need it.
Can our advisers work in Pixen with us?
Yes. Consultants and advisers can work inside your workspace, so their work stays with you and every assumption keeps its source.